Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Open-Label Study of Ravulizumab in Pediatric PNH
2017-002820-26Phase 3Unknown
- Sponsor
- Alexion Pharmaceuticals
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ravulizumab in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Alexion Pharmaceuticals. Primary endpoint: PK/PD parameters (trough and peak). Status: unknown.
02
Drugs
ravulizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2017-002820-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002820-26.